Molbio Diagnostics544866Diagnostics
Jefferies initiated a buy on recently listed Molbio Diagnostics with a target price of Rs 1,600 per share
- Target price
- Rs 1,600 per share
- Sales from TruNet
- 86 percent
- FY26-29 revenue growth estimate
- 22 percent
- FY26-29 PAT growth estimate
- 47 percent
Heard on Live TV News Channel between 08:20:25 - 08:21:40 IST.
- Jefferies initiated coverage with a buy call, citing innovation and a robust product pipeline.
- 86% of sales come through TruNet platform, operating in a crowded market.
- Jefferies expects FY26-29 revenue growth of 22% and PAT growth of 47%, driven by scaling of existing products and operating leverage.
Also from Molbio Diagnostics
Molbio Diagnostics Ltd shareholder sells 2.60% stake, holding falls to 8.92%
1 Oct 2026
Molbio Diagnostics Ltd shareholder sells 2.06% stake
1 Oct 2026
Cost Auditor Re-appointed for FY 2026-27
25 Sep 2026
Source: Live TV News Channel · 30 Sep 2026
The call above is Jefferies's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.